Oruka Therapeutics, Inc. Increase (Decrease) in Accounts Payable, Related Parties
Oruka Therapeutics, Inc. (ORKA) reported Increase (Decrease) in Accounts Payable, Related Parties of -$9.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties · last filed 2026-08-10
- Oruka Therapeutics, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2026-06-30 was -$3.00M.
- Oruka Therapeutics, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2026-03-31 was $3.00M.
- Oruka Therapeutics, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2025-12-31 was $1.00K.
- Oruka Therapeutics, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2025-09-30 was -$111.00K.
- Oruka Therapeutics, Inc. increase (decrease) in accounts payable, related parties for fiscal 2025 was -$6.01M.
| Period end | Increase (Decrease) in Accounts Payable, Related Parties 2 month | Increase (Decrease) in Accounts Payable, Related Parties 3 month | Increase (Decrease) in Accounts Payable, Related Parties 5 month | Increase (Decrease) in Accounts Payable, Related Parties 6 month | Increase (Decrease) in Accounts Payable, Related Parties 8 month | Increase (Decrease) in Accounts Payable, Related Parties 9 month | Increase (Decrease) in Accounts Payable, Related Parties 11 month | Increase (Decrease) in Accounts Payable, Related Parties 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$9.00K 10-Q · filed 2026-08-10 | -$8.00K derived: sum of 3 quarters · filed 2026-08-10 | -$119.00K derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-13 | $3.00M derived: sum of 2 quarters · filed 2026-05-13 | $2.88M derived: sum of 3 quarters · filed 2026-05-13 | $2.19M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$110.00K derived: sum of 2 quarters · filed 2026-03-12 | -$808.00K derived: sum of 3 quarters · filed 2026-08-10 | -$6.01M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$809.00K derived: sum of 2 quarters · filed 2026-08-10 | -$6.01M 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | -$698.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$5.90M 10-Q · filed 2026-08-10 | ||||||
| 2025-03-31 | -$5.21M 10-Q · filed 2026-05-13 | |||||||
| 2024-12-31 | $6.02M 10-K · filed 2026-03-12 | |||||||
| 2024-09-30 | $6.36M 10-Q · filed 2025-11-12 | |||||||
| 2024-06-30 | $15.44M 10-Q · filed 2025-08-11 | |||||||
| 2024-03-31 | $5.83M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |